The U.S. Drug of Abuse (DoA) Testing Market size will reach USD 4.6 billion by 2027 and is expected to develop at a CAGR of 9.7% during the forecast period (2021-2027), according to VynZ Research. For the forecast year 2021-2027, as well as the historical period 20152020, the U.S. Drug of Abuse (DoA) Testing Market has been studied. The research report provides a comprehensive and insightful examination of the U.S. Drug of Abuse (DoA) Testing Market and includes market analysis on segmentation, dynamics, competition, and regional development. It considers the U.S. Drug of Abuse (DoA) Testing Market's CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, pricing, and other significant parameters. The forecasts in the report are based on wellestablished research methodology and assumptions. Get the sample copy of the Market Research @ https://www.vynzresearch.com/healthcare/us-drug-of-abuse-testing-market/requestsample Individual strategies were examined in the U.S. Drug of Abuse (DoA) Testing Market study, followed by business profiles of U.S. Drug of Abuse (DoA) Testing Market providers. The study includes an 'Industry Landscape' section that provides readers with a comprehensive view and firms’ market share analysis of major industry players in the Market. Most of the major players in the U.S. Drug of Abuse (DoA) Testing Market are profiled in the report. The strengths and weaknesses, business developments, recent innovations, mergers and acquisitions, expansion plans, U.S. footprint, market presence, and product portfolios of key market competitors are all covered in the company profiling section. The following are some of the major and developing players in the Market:
Siemens AG
Danaher Corporation
Merck KGaA
Laboratory Corporation of America Holdings
Express Diagnostics Int'l, Inc.
Quest Diagnostics Inc.
Waters Corporation
Abbott Laboratories
Psychemedics Corporation
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche AG
Breakdown of The Segments: